UGN-102
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bladder Cancer
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Trial Timeline
Mar 1, 2022 → Feb 1, 2028
NCT ID
NCT05243550About UGN-102
UGN-102 is a phase 3 stage product being developed by UroGen Pharma for Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05243550. Target conditions include Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder.
What happened to similar drugs?
20 of 20 similar drugs in Bladder Cancer were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05243550 | Phase 3 | Active |
| NCT05136898 | Phase 3 | Completed |
| NCT04688931 | Phase 3 | Terminated |
| NCT03558503 | Phase 2 | Completed |
Competing Products
20 competing products in Bladder Cancer